Article Details
Retrieved on: 2018-02-15 22:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Following Genocea's $55 million public offering led by <b>New Enterprise</b> <b>Associates</b>, NEA partner Ali Behbahani will join the board of the cancer vaccine developer $GNCA. → Aimmune Therapeutics $AIMT, the biotech being watched for its peanut allergy drug, has recruited two more allergy experts to his ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here